The JAK2 inhibitor ruxolitinib reduces splenic haematopoiesis but does not reverse MF in the Gata1low mice,66 and ruxolitinib is currently approved by the Food and Drug Administration (FDA) only for palliation of splenomegaly and MF‐associated symptoms. Here, JAK2 is linked to Splenomegaly.